Board of Directors

Our Board of Directors is composed of professors, medical doctors, researchers, clinical trials specialists, and business professionals who are committed to advancing the Foundation's mission and goals.

Eleanor McFadden, MS

Board Chair, Frontier Science Foundation; Managing Director, Frontier Science (Scotland) Ltd.

Eleanor McFadden has almost 40 years of experience in the management of clinical trials, including more than 20 years spent with Frontier Science Foundation in Boston, MA, US where she was Director of the Coordinating Center for the Eastern Cooperative Oncology Group. In 2000, Ms. McFadden returned to Great Britain to establish a Frontier Science office in in the Scottish Highlands. She has authored a book, Management of Data in Clinical Trials, and is a past President of the Society for Clinical Trials. Ms. McFadden received the Life Science Business Leadership prize at the 2015 Scottish Enterprise Life Sciences Awards. She has served on many review panels for various organisations such as the US National Cancer Institute, Cancer Research UK, the Irish Health Research Board and has been chair of the International Panel for the UK Clinical Research Network review and registration of UK Clinical Trials Units.

Gregory Pavlov

Treasurer, Frontier Science Foundation

For the past 40 years Gregory Pavlov has been engaged in clinical trials data management and related research efforts in a range of technical and managerial capacities, including database administrator, programmer analyst, director of data management and computing for the ACTG and IMPAACT clinical trials, and director of the Frontier Science Amherst, NY office. Mr. Pavlov was president of Frontier Science from July 2014 until July 2017. Throughout his career, Mr. Pavlov created systems that facilitated national and international trials collaboration including clinical trials networks such as the CALGB, ECOG, IBCSG and RTOG; trials conducted by the Dana-Farber and other research institutes; and various industry sponsors.

Urania Dafni, ScD

Director of Frontier Science Foundation-Hellas

Dr. Urania Dafni, Director of Frontier Science Foundation–Hellas (FSF-H) and Professor of Biostatistics at the University of Athens, is a founding member and served as President (2005-2007) of the Eastern Mediterranean Region of the International Biometric Society (IBS). Dr. Dafni was the Scientific Director of the National Syndromic Surveillance program for the Athens 2004 Olympic Games and is currently a member of the Board of Directors of the Hellenic Center for Disease Control and Prevention, Ministry of Health. She is a member of the Education committee of IBS, the American Society of Clinical Oncology (ASCO), and the European Society for Medical Oncology (ESMO), reflecting her over 25-year experience in Clinical trials.

David DeMets, PhD

Professor Emeritus, Department of Biostatistics & Medical Informatics, University of Wisconsin Madison

David DeMets is the Max Halperin Professor of Biostatistics, Emeritus, and former Chair of the Department of Biostatistics and Medical Informatics at the University of Wisconsin Madison. He has authored numerous statistical methods papers, collaborative scientific and clinical papers, book chapters, and has co-authored four books, Fundamentals of Clinical Trials, Data Monitoring in Clinical Trials: A Case Studies Approach, Data Monitoring Committees in Clinical Trials: A Practical Perspective, and Statistical Methods for Clinical Trials. Dr. DeMets has served on numerous NIH and industry-sponsored Data Safety and Monitoring Committees for clinical trials in diverse disciplines. He served on the Board of Directors of the Society for Clinical Trials (1983-1987), American Statistical Association (1987-89), as well as having been President of the Society for Clinical Trials (1989) and President of the Eastern North American Region (ENAR) of the Biometric Society (1993). Dr. DeMets was Elected Fellow of the International Statistics Institute in 1984, the American Statistical Association in 1986, the Association for the Advancement of Science in 1998, the Society for Clinical Trials in 2006 and the American Medical Informatics Association in 2008. In 2013, he was elected as a member of the Institute of Medicine, now the National Academy of Medicine. Dr. DeMet’s research interests include the design, data monitoring and analysis of clinical trials, especially large Phase III randomized clinical trials. He is well known for his work on sequential statistical methods for monitoring interim data for early evidence of intervention benefit or possible harm. See Dr. DeMet’s Faculty page at the University of Wisconsin.

Richard Gelber, PhD

Professor of Pediatrics (Biostatistics), Harvard Medical School; Professor of Biostatistics, Harvard T.H. Chan School of Public Health

Dr. Richard Gelber is Professor of Pediatrics (Biostatistics) at Harvard Medical School and Professor in Biostatistics at the Department of Biostatistics, Harvard T.H. Chan School of Public Health, and the Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute. He is a recognized expert for his contributions to the design and analysis of many important clinical trials, improving cure rates for pediatric leukemia, pediatric AIDS and perinatal transmission of HIV, and breast cancer. Dr. Gelber served as the Statistical Director for the International Breast Cancer Study Group (IBCSG) at the Dana-Farber Cancer Institute for over 40 years (1977 to 2018), and has collaborated with the Breast International Group (BIG) since 1998, serving in the BIG Executive Board from 2010 to 2014. He has developed statistical methodologies for quality of life (Q-TWiST) and for subpopulation analyses (STEPP), both designed to increase the relevance of clinical trial data for use in patient-care decision-making. Dr. Gelber has been awarded numerous honors including the prestigious Brinker Award for Scientific Distinction in Clinical Research, Susan G. Komen for the Cure, and an honorary Doctorate in Medicine from the University of Göteborg, Sweden.

Lawrence Huffman, MBA


Mr. Lawrence Huffman’s career includes over 30 years in the health industries, with extensive international experience. He worked at the EU Commission in Brussels (1979-1980). At Lederle Division Hospital Products, he was General Manager in the UK (1980-1984), was Vice-President in Asia/Pacific and Regional Director, Canada and Latin America (1984-1989). Mr. Huffman was President of Robert et Carrière-Lederlé in Paris, France (1989-1994). He was a Corporate Vice President at MediSense, Inc. in Waltham, Massachusetts (1994-1996); Vice President Abbott Diabetes Care 1996-1999 and 2004-2009 and Vice President of International Sales and Business Development at TheraSense, Inc. (1999-2004) both in Alameda, California. Mr. Huffman is currently based in New York, NY as a Venture capital consultant. He was educated in Electrical Engineering at the University of Pennsylvania, and earned an MBA in Accounting and Finance at the Wharton School. Read Mr. Huffman’s Career Experience summary here.

Mary Long, BS

Manager, Project Management, eClinical Solutions

Mary Long has been working in data management and cancer research for over 25 years. She has worked for ECOG-ACRIN Cancer Group, and for over ten years Mary was Senior Director of Administrative Programs for Eastern Cooperative Oncology Group, where she was involved in operational activities for all phases of clinical research with direct and indirect management of operational project leaders and undertakings such as study life cycle management, publication planning, literature reviews and advisory boards. Mary Steele Long is currently the Manager of Project Management with eClinical Solutions. Mary’s entire CV is available here.

Frank Rockhold, ScM, PhD

Professor of Biostatistics and Bioinformatics, Duke Clinical Research Institute; Managing Partner of HunterRockhold, Inc.

Frank Rockhold, ScM, PhD has had diverse research interests and consulting experience in industry and academia including clinical trials design, data monitoring, benefit/risk, and most recently, safety and pharmacovigilance. He has been a leader in the scientific community in promoting data disclosure and transparency in clinical research. Dr. Rockhold is a full Professor of Biostatistics and Bioinformatics at Duke Clinical Research Institute and Managing Partner of HunterRockhold, Inc. His 40+ year career includes senior research positions at Lilly, Merck, and GlaxoSmithKline, where he recently retired as Senior Vice President of Global Clinical Safety and Pharmacovigilance. Dr. Rockhold has also held faculty appointments at six different universities. He served for 9 years on the board of directors of the non-profit Clinical Data Interchange Standards Consortium (CDISC), most recently as Chairman, and is past president of the Society for Clinical Trials. He is a past member of the PCORI Clinical Trials Advisory Panel. Dr. Rockhold holds a BA in Statistics from The University of Connecticut, an ScM in Biostatistics from Johns Hopkins University, and a PhD in Biostatistics from the Medical College of Virginia at Virginia Commonwealth University. He is a Fellow of the American Statistical Association and the Society for Clinical Trials and an Accredited Professional Statistician, PStat®. He is widely published in major scientific journals across a wide variety of research topics. Dr. Rockhold’s CV is available here.

Thelma Zelen

Frontier Science Foundation Director Emeritus

Thelma Zelen has been involved with Frontier Science since shortly after its founding in 1975. She has been a constant source of support toward the growth of Frontier Science both domestically and internationally. She is familiar with every aspect of the organization and has played key roles in the foundation’s administration and development. Thelma was the first administrative officer of Frontier Science. Until recently, Thelma served as the Chief Administrative Director for the Boston Office.